Organization: Health Canada
Year: 2022
Month: June
Request Number: A-2022-000078
Request Summary: The Module 1.3.1 Note to reviewer indicating the brand name of the reference drug product and the dosage form of the generic drug in the list of generic drug submissions under review for the medicinal ingredient Gabapentin. The Screening Acceptance Letter from Health Canada to any and all generic drug manufacturers confirming completion of screening of any and all Abbreviated New Drug Submissions for gabapentin which appear on the list of Generic Drug Submissions Under Review (GSUR).
Disposition: Disclosed in part
Number of pages: 3